Discontinuation of antipsychotic medication-time to rethink trial design
Speyer, H.,
Begemann, M., Albert, N., Weller, A., Nordentoft, M.,
Veling, W.,
Sommer, I. E., Allott, K. & Killackey, E.,
Oct-2020,
In : The Lancet. Psychiatry. 7,
10,
p. 841-842 2 p.Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review
APA
Speyer, H.
, Begemann, M., Albert, N., Weller, A., Nordentoft, M.
, Veling, W., Sommer, I. E., Allott, K., & Killackey, E. (2020).
Discontinuation of antipsychotic medication-time to rethink trial design.
The Lancet. Psychiatry,
7(10), 841-842.
https://doi.org/10.1016/S2215-0366(20)30340-0Author
Speyer, Helene ; Begemann, Marieke ; Albert, Nikolai ; Weller, Amber ; Nordentoft, Merete ; Veling, Wim ; Sommer, Iris E ; Allott, Kelly ; Killackey, Eóin. / Discontinuation of antipsychotic medication-time to rethink trial design. In: The Lancet. Psychiatry. 2020 ; Vol. 7, No. 10. pp. 841-842.
Harvard
Speyer, H
, Begemann, M, Albert, N, Weller, A, Nordentoft, M
, Veling, W, Sommer, IE, Allott, K & Killackey, E 2020, '
Discontinuation of antipsychotic medication-time to rethink trial design',
The Lancet. Psychiatry, vol. 7, no. 10, pp. 841-842.
https://doi.org/10.1016/S2215-0366(20)30340-0Standard
Discontinuation of antipsychotic medication-time to rethink trial design. / Speyer, Helene; Begemann, Marieke; Albert, Nikolai; Weller, Amber; Nordentoft, Merete; Veling, Wim; Sommer, Iris E; Allott, Kelly; Killackey, Eóin.
In:
The Lancet. Psychiatry, Vol. 7, No. 10, 10.2020, p. 841-842.
Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review
Vancouver
Speyer H
, Begemann M, Albert N, Weller A, Nordentoft M
, Veling W et al.
Discontinuation of antipsychotic medication-time to rethink trial design.
The Lancet. Psychiatry. 2020 Oct;7(10):841-842.
https://doi.org/10.1016/S2215-0366(20)30340-0
BibTeX
@article{8d5f8c1105a041caaffb533f8d080b8a,
title = "Discontinuation of antipsychotic medication-time to rethink trial design",
keywords = "Antipsychotic Agents/therapeutic use, Humans, Medication Adherence, Patient Dropouts, Patient Selection, Psychotic Disorders/drug therapy, Randomized Controlled Trials as Topic, Recurrence, Research Design",
author = "Helene Speyer and Marieke Begemann and Nikolai Albert and Amber Weller and Merete Nordentoft and Wim Veling and Sommer, {Iris E} and Kelly Allott and E{\'o}in Killackey",
year = "2020",
month = oct,
doi = "10.1016/S2215-0366(20)30340-0",
language = "English",
volume = "7",
pages = "841--842",
journal = "The Lancet. Psychiatry",
issn = "2215-0366",
publisher = "ELSEVIER SCI LTD",
number = "10",
}
RIS
TY - JOUR
T1 - Discontinuation of antipsychotic medication-time to rethink trial design
AU - Speyer, Helene
AU - Begemann, Marieke
AU - Albert, Nikolai
AU - Weller, Amber
AU - Nordentoft, Merete
AU - Veling, Wim
AU - Sommer, Iris E
AU - Allott, Kelly
AU - Killackey, Eóin
PY - 2020/10
Y1 - 2020/10
KW - Antipsychotic Agents/therapeutic use
KW - Humans
KW - Medication Adherence
KW - Patient Dropouts
KW - Patient Selection
KW - Psychotic Disorders/drug therapy
KW - Randomized Controlled Trials as Topic
KW - Recurrence
KW - Research Design
U2 - 10.1016/S2215-0366(20)30340-0
DO - 10.1016/S2215-0366(20)30340-0
M3 - Comment/Letter to the editor
C2 - 32949515
VL - 7
SP - 841
EP - 842
JO - The Lancet. Psychiatry
JF - The Lancet. Psychiatry
SN - 2215-0366
IS - 10
ER -
